Management of end-stage heart failure: a perspective on the Arab Gulf states

Waleed Al Habeeb, Garrick C. Stewart, Gilbert H. Mudge

From the Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA

Correspondence: Gilbert H. Mudge, MD • Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, MA 02115, USA • T: +1-617-732-7140 F: +1-617-264-5265 • gmudge@partners.org • Accepted for publication August 2009

Ann Saudi Med 2009; 29(6): 460-466

The management of patients with end-stage heart failure has emerged as one of the major challenges in cardiovascular medicine. There has been considerable progress in the understanding of heart failure pathophysiology leading to medical therapies that impact the prognosis and symptoms of chronic heart failure.1-4 Therapeutic options for end-stage failure, however, remain limited and include intravenous inotrope therapy, heart transplantation, or mechanical circulatory support.5,6 These advanced therapeutic modalities are available at select centers in the United States and Europe, but are not routinely considered in other global regions. The Arab Gulf is one such region. The primary barriers to widespread adoption of these advanced treatments are limited financial resources, lack of medical expertise, and cultural attitudes about organ procurement. The Arab Gulf is united by a common religion and culture and has a rapidly expanding medical expertise and proficiency. This review will discuss the management of end-stage heart failure in the Gulf States, with an emphasis on therapies best utilized within a framework of regional cooperation and coordination.

Incidence of heart failure

The incidence of cardiovascular disease and heart failure is projected to increase substantially in the Arab Gulf States as the region completes an epidemiological transition fueled by socioeconomic change.7 Even as access to health technology increases, trends in urbanization, inactivity and receding infectious pandemics are allowing cardiovascular diseases to become the leading cause of morbidity and mortality. Hypertension is now estimated to affect more than one fourth of the Saudi population.8 The traditional high fiber, low fat diet has been replaced by a Western diet higher in fat. This change in dietary intake along with a more sedentary lifestyle has led to obesity in 35% of Saudi’s as defined by a body mass index (BMI) ≥30 kg/m² and diabetes mellitus in 23.7%.9-13 With atherosclerotic risk factors on the rise, coronary artery disease and ischemic cardiomyopathy will become more prevalent.14 Ischemic heart disease is already the leading cause of heart failure in Western Europe and the United States, countries that were the earliest to complete the epidemiologic transition.15,16 For example, heart failure currently accounts for over $35 billion in health care costs in the United States and remains the leading hospital discharge diagnosis in patients over the age of 65.17

It is estimated that 5-10% of heart failure patients have end-stage, refractory disease.18 These patients suffer from extreme exercise intolerance, debilitating dys-
Heart failure patients are now less likely to suffer sudden cardiac death as a result of widespread use of neurohormonal antagonists and ICDs. These therapies have prolonged survival with heart failure leading to a larger proportion of patients in the later stages of this progressive disease who suffer the hemodynamic consequences of refractory fluid congestion and end-organ underperfusion. The increasing prevalence and severity of heart failure combined with the very poor quality of life and dismal prognosis mandate that other therapies be considered for heart failure patients living in the Arab Gulf States.

**Medical therapies for advanced heart failure**

The major advances in heart failure therapies have been primarily seen with systolic heart failure with a reduced ejection fraction. There is no debate that beta-adrenergic blockers, angiotensin converting enzyme (ACE) inhibitors, and angiotensin-receptor blockers (ARBs) offer an improved survival, and the frequency of their administration is emerging as a quality of care benchmark. Aldosterone antagonists have a clear role in post-infarction patients and symptomatic heart failure, although serum potassium and renal function must be carefully monitored. Hydralazine and nitrates continue to have a time-honored place in heart failure management, especially in those intolerant of ACE-inhibitors or ARBs or persistent renal compromise. Loop diuretic therapy has a central role for symptom relief but has not been shown to confer a survival benefit. Despite being available since the 18th century, digitalis glycosides such as digoxin reduce hospitalizations for heart failure and provide modest symptomatic relief, but they do not prolong survival.

In patients with diastolic heart failure, the most effective therapies will include diuresis, control of blood pressure, and maintenance of sinus rhythm. There have been no studies demonstrating a robust mortality benefit of any agent in heart failure with a preserved ejection fraction even though such patients may constitute half of all patients with heart failure.

Most medical therapies have been directed toward NYHA Functional Class II-III or AHA/ACC Stage C heart failure and have a limited role once the evolution of heart failure have moved to Class IV NYHA or Stage D (Tables 1 and 2). In fact, one definition of end-stage heart failure is an intolerance to or failure of conventional therapy.

**Cardiac resynchronization therapy**

Many heart failure patients with a low ejection fraction often also have interventricular conduction delay, as manifest by a widened QRS complex (>120 msec) on electrocardiogram from either a bundle branch block or nonspecific conduction delay. This delay creates dysynchronous contraction of the left ventricle and can contribute to remodeling, mitral regurgitation and symptoms of congestion. Class III-IV Heart failure patients with reduced ejection fraction and conduction delay (QRS width >120-150 msec) may benefit from cardiac resynchronization therapy (CRT), also known as biventricular pacing. Pacemaker leads are placed in the right ventricular apex and the lateral free wall of the left ventricle via the coronary sinus to “resynchronize” contraction of the left ventricular. This may lead to reverse remodeling, decrease mitral regurgitation and a mortality benefit in select patients. Not every patient will respond to CRT. Prospectively identifying responders and nonresponders is an active area of research.

**Heart failure management programs**

The primary goals in the management of end-stage heart failure are to reduce hospitalizations and to improve quality of life. Disease management programs have been shown to be effective in this regard, providing a structured continuity between the hospital discharge and the home setting. Pre-discharge education is central to its success. A team of providers that includes physicians, nurses, nurse practitioners, physicians assistants and pharmacists, working with established guidelines, can provide meaningful interventions when there is frequent communication with outpatients. For example, daily weights can be monitoring to guide adjustments of diuretic dosage and home blood pressure readings can be used to adjust afterload reduction. Implantable technology for daily estimation of left heart filling pressures can provide additional he-
Table 1. New York Heart Association functional class.

| Class | Description |
|-------|-------------|
| I     | No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). |
| II    | Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. |
| III   | Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. |
| IV    | Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased. |

Table 2. Stages of heart failure.

| Stage | Description |
|-------|-------------|
| A     | At risk for heart failure but without structural heart disease or symptoms of heart failure |
| B     | Structural heart disease but without signs of symptoms of heart failure |
| C     | Structural heart disease with prior or current symptoms of heart failure |
| D     | Refractory heart failure requiring specialized interventional (e.g. mechanical circulatory assist devices, intravenous inotropes or vasodilators) |

Inotropic therapy

Many patients with refractory congestive symptoms and low cardiac output despite conventional therapy will benefit from infusion of a positive inotrope. Most commonly performed as an inpatient strategy, select patients can be transitioned to outpatient therapy infusion therapy once safe administration has been demonstrated. Though intravenous inotropes such as dobutamine (a beta-adrenergic receptor agonist) or milrinone (a phosphodiesterase-3 inhibitor) provide short-term improvements in congestive symptoms and cardiac output, this comes at the price of increased risk of ventricular tachycardia and direct cardiac myocyte toxicity. Prophylactic ICD are routinely placed to protect patients on chronic inotropic infusions from malignant tachyarrhythmias. Continuous outpatient inotropic therapy may be administrated through a tunneled central venous catheter and can help to maintain end-organ perfusion in patients awaiting heart transplantation.

Heart transplantation

Orthotopic cardiac transplantation remains the definitive therapy for terminal heart failure. Surgical techniques can be acquired by many tertiary care centers. Recipient criteria have been well-established and immune suppression protocols have been standardized. Long-term post-transplantation care is managed by an integrated team of cardiologists, nurses, nurse practitioners, physicians assistants and pharmacists. After cardiac transplantation patients can achieve an acceptable 5-year survival of 70%, a 10-year survival of 60%, and markedly improved quality of life. Despite these impressive results in select patients, the ultimate potential for cardiac transplantation to stem the tide of the rising heart failure epidemic remains limited. Even in the United States, donor organ availability has remained static even as the waiting list for heart transplant grows.

The primary barrier to cardiac transplantation in the Gulf States is the ad hoc organization of donor supply. While a limited number of centers have been able to perform the intermittent transplant, no program in the Gulf has achieved sufficient experience that would meet program certification goals of national regulatory bodies. Saudi Arabia is the only country within the Gulf region with a solid organ transplant organization, the Saudi Center for Organ Transplantation (SCOT), and King Faisal Specialist Hospital in Riyadh is the only heart transplant center. In 2008, the last year for which data is available, there were 19 cardiac transplantations in SCOT, preceded by 12 transplants in the year prior. To put this in perspective, the United States Center for Medicare Services requires advanced heart failure programs to perform 12 transplants per year for 3 years to secure certification. The absence of a well-organized solid organ procurement apparatus in the Gulf States has prevented the expansion of cardiac transplantation as a viable modality of therapy for select end-stage heart failure patients.

Sadly, mortality is rapidly rising in the Gulf states from motor vehicle collisions as well as cerebral vascular accidents from poorly controlled hypertension—the most common conditions causes brain death while preserving the potential for organ donation. While automobile accidents and strokes present a significant challenge to public health authorities, they also represent an opportunity to coordinate donor management, procurement and distribution. The Gulf Cooperative Countries (GCC) have already established political, travel and trade alliances. Established in 1981, the six GCC countries include Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain with a population base approaching 41 million and a unifying culture. Organization of solid
organ transplantation dovetails with the GCC charter which specifically outlines a goal of integration and interconnection between members states in all fields to encourage cooperation and joint ventures.

Many existing organ procurement organizations cross political boundaries to serve the collective transplant need. In the United States, the New England Organ Bank represents 6 states and Bermuda, with a population base of 11.2 million. The Eurotransplant International Foundation serves the transplant needs of Austria, Belgium, Germany, Luxembourg, the Netherlands, Slovenia and Croatia, with a population of 124.5 million and coordinated 6,600 solid organ donations. In order to address the current and future needs of all solid organ transplantation for the GCC, a coordinated transnational organ procurement organization representing the interests of the populations of all the Gulf States must be considered.

It is beyond the scope of this article to discuss the many religious and cultural issues surrounding solid organ transplantation. Organ donation, harvest and transplantation are a relatively new cultural concept in the Islamic and Arabic world and subject to a variety of interpretations. Renal transplantation, given its longer history, has wider acceptance than other solid organ programs.61-63 The Islamic medical community may have different interpretations than the general community, and at the present time, many medical centers follow the dictum that organ donation can be religiously rewarded—And if any one saved a life, it would be as if he saved the life of the whole people. (Al-Ma‘eda, Chapter 5, Verse 32)64

Ventricular assist devices
Given the immediate limitations to cardiac transplantation in the Gulf States and ultimate limitations of donor supply, ventricular assist devices (VAD) may be the most reasonable option for long-term hemodynamic support.65,66 (Tables 3 and 4) VAD technology has rapidly advanced, and such may now be considered as a reasonable therapy for both transplant eligible patients and those excluded due to conventional co-morbidities.67 VADs provide mechanical circulatory assistance after being placed in parallel to the patient’s own heart which is left in its native anatomic position, unlike the total artificial heart or orthotopic transplantation.68 VADs are broadly categorized as pulsatile pumps or continuous flow rotary devices. Pulsatile assist devices were the first to be developed and the first approved for destination therapy (Heartmate XVE) after the landmark REMATCH trial.69 New technology includes the axial or continuous flow devices.70 These next generation VADs have a lower profile, making them easier to implant even in smaller patients, and, offer quiet, vibration free operation. These continuous flow pumps may also be easier to manage by the patient and their family, and seem to have extended durability compared to the pulsatile technology. By late 2008, there was evidence that the axial flow technologies were emerging as superior technology to the pulsatile devices, and it is anticipated that they might be the technology of choice in the near future. Each of these devices can be managed in the outpatient setting and permit full ambulatory capability.

The clear survival advantage and quality of life for patients receiving VADs compared to medical therapy now justifies their use for circulatory support well beyond the transplant setting. In REMATCH, the implantation of a left-sided VAD was associated with a relative reduction in the risk of death of 48 percent during the entire follow-up period of 4 years and an absolute reduction in the mortality rate of 27 percent at one year.69,71 Quality of life with a VAD is substantially better than that experienced by patients just before VAD support. Many patients move from NYHA Class IV to Class I-II. These results portend an acceptable quality of life for the long-term use of VADs as an alternative to medical therapy for patients in need of cardiac transplantation but who will not receive it.72

Prior to VAD implantation, all patients should be evaluated at cardiac centers with specific expertise in advanced heart failure.73 Oftentimes patients benefit from more aggressive and expert management of their NYHA: New York Heart Association; *Cardiogenic shock may be seen following acute myocardial infarction or cardiac surgery; Implantation should only be considered in patients without potential for recovery; †Smaller individuals may be fitted with available paracorporeal, small-sized pulsatile or newer axial-flow devices.

| Table 3. Indications for ventricular assist device implantation. |
|---------------------------------------------------------------|
| **NYHA functional class IV symptoms**                        |
| Life expectancy <2 years                                     |
| Not a heart transplantation candidate                        |
| Failure to respond to optimal medical management for 60 of the last 90 days |
| Left ventricular ejection fraction ≤25%                       |
| Refractory cardiogenic shock or cardiac failure†             |
| Peak oxygen consumption ≤12 ml/kg/min with cardiac limitation |
| Continued need for intravenous inotropic therapy limited by symptomatic hypotension, decreasing renal function or worsening pulmonary congestion |
| Recurrent symptomatic sustained ventricular tachycardia or ventricular fibrillation in the presence of an untreatable arrhythmogenic pathologic substrate |
| Body surface area >1.5 m²†                                    |

NYHA: New York Heart Association; †Cardiogenic shock may be seen following acute myocardial infarction or cardiac surgery; Implantation should only be considered in patients without potential for recovery; †Smaller individuals may be fitted with available paracorporeal, small-sized pulsatile or newer axial-flow devices.
heart failure, including a restructuring of their medical regimen. If symptoms remain refractory to standard therapy, patients may be considered for VAD implantation in one of three categories: 1) “Bridge to Recovery” for patients who are not expected to need long term support; 2) “Bridge to Transplantation” for patients suitable for cardiac transplant but who are too ill to wait until an organ becomes available; 3) “Destination Therapy” for patients needing long-term support but who are ineligible for cardiac transplantation by conventional criteria. The distinction between “bridge to transplant” and bridge to destination” may be too arbitrary. There will be inevitable “bridge to transplant” patients that develop complications precluding successful transplant, and there will be inevitable “bridge to destination” patients who improve sufficiently to be able to be transplanted without complication. Hence, “bridge to decision” is perhaps a more honest representation of options to many patients and their families.

The ample costs associated with VAD implantation are contingent on the type of device used, length of hospital stay, country-specific health economics, and the nature of the underlying disease. The mean total costs for VAD implantation is US $210,132 over an average period of 9.5 months. This does not meet current thresholds for cost-effectiveness, as expensive technologies can be cost effective while inexpensive ones can be cost ineffective. In the Gulf States, most of the health expenses are carried by the central governments and providing such expensive therapy may be considered a burden unless proven cost-effective. The ultimate comparison will balance the costs of treating heart failure with the incalculable costs of death and disability.

Any cost-effectiveness analysis must also take into account the rapid evolution of technology used. Since the axial flow devices are smaller, simpler to use, and more durable, it can be anticipated that they will also be more cost effective. In addition, the cost of a new medical technology usually declines as it becomes more widespread and management issues standardized. Continued improvements to the next generation of devices can be anticipated to extend durability and reduce complication rates.

Conclusions
The management of heart failure is both a challenge and an opportunity for the health care systems of the Gulf region. Advanced therapies for terminal heart failure remain elusive. While cardiac transplantation remains a potential option, there are logistical limitations in the Arabic world at the present time that limit widespread applicability. The new technologies of mechanical circulatory assistance may be a better option for end-stage patients, and requires thoughtful analysis and candid discussion about the priorities of health care resource allocation. Heart failure patients in the Gulf are deserving of these advanced therapies that will improve the quality and length of their lives.

Acknowledgment
This research is supported by a scholarship to Dr. Al Habeeb by the King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

### Table 4. Contraindications to ventricular assist device implantation.

| Relative contraindications                                      |
|---------------------------------------------------------------|
| Age>65 years, unless minimal or no other clinical risk factors|
| Chronic kidney disease with serum creatinine level >3.0 mg/dL  |
| Severe chronic malnutrition (BMI<21 kg/m² in males and <19 kg/m² in females) |
| Morbid obesity (BMI>40 kg/m²)                                  |
| Mechanical ventilation                                         |
| Severe mitral stenosis, moderate to severe aortic insufficiency, or uncorrectable mitral regurgitation |
| Absolute contraindications                                    |
| Reversible, transient causes of heart failure                 |
| Recent or evolving stroke                                      |
| Neurologic deficits impairing the ability to manage device     |
| Coexisting terminal condition (e.g., metastatic cancer, cirrhosis) |
| Abdominal aortic aneurysm ≥5 cm                                |
| Biventricular failure in patients older than 65 years          |
| Active systemic infection or major chronic risk for infection  |
| Fixed pulmonary or portal hypertension                         |
| Severe pulmonary dysfunction (e.g., FEV₁<1 liter)              |
| Impending renal or hepatic failure                             |
| Multiple organ system failure                                  |
| Inability to tolerate anticoagulation                          |
| Heparin induced thrombocytopenia                                |
| Significant underlying psychiatric illness or lack of social support that may impair ability to maintain and operate VAD |

BMI: body mass index; COPD: chronic obstructive pulmonary disease; FEV₁: forced expiratory volume in 1 second. Adapted from Wilson, et al.81
REFERENCES

1. Jessup M, Abraham WT, Case DE, Feldman AM, Francis GS, Ganitsis TG, et al. 2009 focused update: ACC/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009 Apr 14;119(14):1977-2016.

2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganitsis TG, et al. 2009 focused update: ACC/AHA guidelines for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20;112(12):e154-235.

3. HFAA 2006 Comprehensive Heart Failure Practice Guideline. Journal of cardiac failure. 2006 Feb;12(1):e1-2.

4. Swedberg K, Cleland JG, Dargie H, Drexler H, Filali F, Komajda M, et al. Guidelines for diagnosis and treatment of chronic heart failure: executive summary update (2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. European heart journal. 2006 Jun;27(11):1115-53.

5. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. Jama. 2002 Feb 6;287(5):628-40.

6. Levy WC, Mozaffarian D, Linker DT, Sudrahad SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2005 Mar 21;111(11):1424-32.

7. Russo MJ, Gelijns AC, Stevenson LW, Sampat B, Aaronson KD, Renlund DG, et al. The cost of medical management in advanced heart failure during the final two years of life. Journal of the American College of Cardiology. 2008 Feb 18;45(1):58-1.

8. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation. 2004 Jun 11;109(22):2685-91.

9. Teuteberg JJ, Lewis EF, Nohria A, Tsang SW, Jarcho JA. Biventricular pacing. The New England journal of medicine. 2005 Jul 28;352(4):288-94.

10. Jarcho JA, Biventricular pacing. The New England journal of medicine. 2005 Jul 28;352(4):288-94.

11. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of angiotensin-converting-enzyme inhibitors on mortality and morbidity in patients taking angiotensin-converting enzyme inhibitors: the BACE-Added Trial. Lancet. 2003 Sep 6;362(9386):767-71.

12. Jessup M, Brozena S. Heart failure. The New England journal of medicine. 2005 May 13;352(19):1905-12.

13. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The New England journal of medicine. 2001 Dec 6;345(23):1767-75.

14. Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the ECHO-ADDITION-Trial. Lancet. 2005 Jan 29;365(9466):83-8.

15. American Heart Association. Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008 Jan 29;117(4):e24-146.

16. Redfield MM. Heart failure—an epidemic of uncertain proportions. The New England journal of medicine. 2002 Oct 3;347(18):1442-3.

17. Lewis DS, Austin PC, Roulault JI, Liu PP, Nairn M, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. Jama. 2003 Nov 19;290(19):2691-7.

18. Levy WC, Mozaffarian D, Linker DT, Sudrahad SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2005 Mar 21;111(11):1424-32.

19. Russo MJ, Gelijns AC, Stevenson LW, Sampat B, Aaronson KD, Renlund DG, et al. The cost of medical management in advanced heart failure during the final two years of life. Journal of the American College of Cardiology. 2008 Feb 18;45(1):58-1.

20. Josephson M, Wellens HJ. Implantable defibrillators and sudden cardiac death. Circulation. 2004 Jun 11;109(22):2685-91.

21. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials of angiotensin-converting-enzyme inhibitors on mortality and morbidity in patients taking angiotensin-converting enzyme inhibitors: the BACE-Added Trial. Lancet. 2003 Sep 6;362(9386):767-71.

22. Jessup M, Brozena S. Heart failure. The New England journal of medicine. 2005 May 13;352(19):1905-12.

23. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. The New England journal of medicine. 2001 Dec 6;345(23):1767-75.

24. Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. Jama. 2002 Feb 20;287(7):883-9.

25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldosterone Evaluation Study Investigators. The New England journal of medicine. 1999 Sep 23;341(10):709-17.

26. Pitt B, Remme W, Zannad F, Neaton J, Martine F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left-ventricular dysfunction after myocardial infarction. The New England journal of medicine. 2003 Apr 3;348(14):1309-17.

27. Webb KT. Aldosterone in congestive heart failure. The New England journal of medicine. 2001 Dec 6;345(23):1899-9.

28. Juurlink DN, Mamdani MM, Lee DS, Kopf A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. The New England journal of medicine. 2003 Nov 1;349(19):1942-9.

29. Taylor AL, Ziesche S, Carson P, D’Agostino R Jr., Fernand K, et al. Combination of isosorbide dinitrate and hyaluronic in blacks with heart failure. The New England journal of medicine. 2004 Nov 11;351(20):2069-77.

30. The Digitalis Investigation Group. The New England journal of medicine. 1999 Feb 10;340(6):552-9.

31. Hauptman PJ, Kelly RA. Digitalis. Circulation. 1999 Mar 9;99(9):1269-70.

32. Aurigemma GP, Gasch WH. Clinical practice. Diastolic heart failure. The New England journal of medicine. 2004 Sep 9;351(11):1097-105.

33. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. Jama. 2003 Jan 8;289(2):194-202.

34. Ritter VL, Westen SA, Redfield MM, Hellermann-Homan JP, Killian J, Yovan BP, et al. Trends in heart failure incidence and survival in a community-based population. Jama. 2004 Jul 21;292(3):344-50.

35. Young JB, Abraham WT, Smith AL, Leon AR, Lieberman R, Wilkoff B, et al. Combined cardionic resynchronization and implantable cardiac defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. Jama. 2003 May 28;290(20):2095-6.

36. Fonarow GC, Stevenson LW, Walden JA, Livingston NA, Steinle AE, Hamilton MA, et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. Journal of the American College of Cardiology. 1997 Sep 30;30(3):725-32.

37. McAlister FA, Lawson FM, Teo KK, Armstrong PW. A systematic review of randomized trials
REFERENCES

of disease management programs in heart fail-
ure. The American Journal of Medicine. 2001 Apr
1;110(5):378-84.

46. Stromberg A, Martensson J, Fridlund B, Levin
LA, Karlsson JE, Dahlostrom U. Nurse-led heart
failure clinics improve survival and self-care be-
haviour in patients with heart failure: results from a
prospective, randomised trial. European heart
journal. 2003 Jun;24(11):1014-23.

47. Stewart S, Marley JE, Horowitz JD. Effects of a
multidisciplinary, home-based intervention on
unplanned readmissions and survival among patients
with chronic congestive heart failure: a randomised
treated trial. Lancet. 1999 Sep
25;354(9164):1077-83.

48. Bourge RC, Abraham WT, Adamson PB, Aaron
MF, Aranda JM, Jr., Magalski A, et al. Random-
ized controlled trial of an implantable continuous
hemodynamic monitor in patients with advanced
heart failure: the COMPASS-HF study. Journal of
the American College of Cardiology. 2008 Mar
18;51(11):1073-9.

49. Stevenson LW. Clinical use of inotropic thera-
py for heart failure: looking backward or forward?
Part II: chronic inotropic therapy. Circulation. 2003
Jul 29;108(4):492-7.

50. Young JB, Moen EK. Outpatient parenteral ino-
trpic therapy for advanced heart failure. J Heart
Lung Transplant. 2000 Aug;19(8 Suppl):S49-57.

51. Stevenson LW. Inotropic therapy for heart fail-
ure. The New England journal of medicine. 1998
Dec 17;339(25):1848-50.

52. Stevenson LW. Clinical use of inotropic thera-
py for heart failure: looking backward or forward?
Part I: inotropic infusions during hospitalization.
Circulation. 2003 Jul 22;108(3):367-72.

53. Hunt SA, Haddad F E. The changing face of heart
transplantation. Journal of the American College
of Cardiology. 2008 Aug 19;52(8):857-98.

54. Taylor DG, Edwards LB, Aurora P, Christie JD,
Dobbs F,Kirk R, et al. Registry of the International
Society for Heart and Lung Transplantation: twenty-
fifth official adult heart transplant report--2008.
J Heart Lung Transplant. 2008 Sep;27(9):942-56.

55. Lietz K, Miller LW. Improved survival of pa-
tients with end-stage heart failure listed for heart
transplantation: analysis of organ procurement
and transplantation network/U.S. United Network
of Organ Sharing data, 1990 to 2005. Journal of
the American College of Cardiology. 2007 Sep
25;50(13):1282-90.

56. Young JB. Heart failure’s near dead and dy-
ing: reconsidering our heart transplant wait list
scheme. Journal of the American College of
Cardiology. 2007 Sep 25;50(13):1291-3.

57. Chen JM, Naka f, Rose EA. New strategies to
expand the donor pool: are they misguided? Nat
Clin Pract Cardiovasc Med. 2004 Nov;1(1):2-3.

58. Saudi Center for Organ Transplantation. Avail-
able from: www.scot.org.sa/annual-report.html.
Heart Transplantation Statistics, Page 98. Ac-
cessed September 2009.

59. El-Shoboubi H, Bener A. Public knowledge and
attitudes toward organ donation and transplanta-
tion: a cross-cultural study. Transplantation pro-
ceedings. 2005 Jun;37(5):1993-7.

60. Shaheen FA, Souqiyeh MZ, Ramprasad K, At-
tar MB. Current issues and problems of transplan-
tation in the Middle East: the Arabian Gulf. Trans-
plantation proceedings. 2001 Aug;33(5):2621-2.

61. Shaheen FA, Souqiyeh MZ. Current status of
renal transplantation in the Kingdom of Saudi
Arabia. Transplantation proceedings. 2004 Jan
Feb;36(1):125-7.

62. Al-Maeda, Chapter 5, Verse 32. Noble Qur’an,
El-Shoubaki H, Bener A. Public knowledge and
attitudes toward organ donation and transplanta-
tion: a cross-cultural study. Transplantation pro-
ceedings. 2001 Aug;33(5):2621-2.

63. Shaheen FA, Souqiyeh MZ. Current status of
renal transplantation in the Kingdom of Saudi
Arabia. Transplantation proceedings. 2004 Jan
Feb;36(1):125-7.

64. Al-Maeda, Chapter 5, Verse 32. Noble Qur’an,
English Translation of the Meanings and Com-
mentry. Dr. Mohammed Muhisin Khan, trans. King
Fahed Complex, 1998, 1998.

65. Cadeiras M, von Baye MP, Deng MC. Car-
diac transplantation: any role left? Heart failure
clinics. 2003 Jul;3(3):9-17.

66. Lietz K, Miller LW. Will left-ventricular assist
device therapy replace heart transplantation in the
foreseeable future? Current opinion in cardiol-
ogy. 2005 Mar;20(2):122-7.

67. Westaby S. Destination therapy: time for real
progress. Nat Clin Pract Cardiovasc Med. 2008
Aug;5(8):477-83.

68. Mudge GH, Jr., Fang JC, Smith C, Couper
G. The physiologic basis for the management of
ventricular assist devices. Clin Cardiol. 2006
Jul;29(7):395-9.

69. Rose EA, Gelijns AC, Moskowitz AJ, Hetjan DF,
Stevenson LW, Dembystok W, et al. Long-term me-
chanical left ventricular assistance for end-stage
heart failure. The New England journal of medi-
cine. 2001 Nov 15;345(20):1435-43.

70. Miller LW, Pagani FD, Russell SD, John R,
Boyle AJ, Aarosen KD, et al. Use of a continuous-
flow device in patients awaiting heart transplanta-
tion. The New England Journal of medicine. 2004
Aug 30;357(8):885-96.

71. Lietz K, Long JW, Xfouri AG, Slaughter MS,
Silver MA, Milano CA, et al. Outcomes of left
ventricular assist device implantation as destina-
tion therapy in the post-REMATCH era: implica-
tions for patient selection. Circulation. 2007 Jul
31;116(3):597-605.

72. Westaby S. Ventricular assist devices as destina-
tion therapy. The Surgical clinics of North
America. 2004 Feb;44(1):91-123.

73. Miller LW, Lietz K. Candidate selection for
long-term left ventricular assist device therapy for
refractory heart failure. J Heart Lung Transplant.
2006 Jul;25(7):736-44.

74. Wilson SR, Mudge GH, Stewart GC, Givertz
MM. Evaluation for a Ventricular Assist Device:
Selecting the Appropriate Candidate. Circulation.
2009.(In Press).

75. Felker GM, Rogers JG. Same bridge, new
destinations rethinking paradigms for mechanical
cardiac support in heart failure. J Am Coll Cardiol.
2006 Mar 7;47(10):S30-2.

76. Beyersdorf F. Economics of ventricular assist
devices: European view. Ann Thorac Surg. 2001
Mar;71(3 Suppl):S192-4; discussion S202-3.

77. Evans RW. Economic impact of mechanical
cardiac assistance. Prog Cardiovasc Dis. 2000 Jul-
Aug;43(1):81-94.

78. Portner PM. Economics of devices. Ann Tho-
rac Surg. 2001 Mar;71(3 Suppl):S199-201; discus-
sion S3-4.

79. Moskowitz AJ, Rose EA, Gelijns AC. The cost
of long-term LVAD implantation. Ann Thorac Surg.
2001 Mar;71(3 Suppl):S195-6; discussion S203-4.

80. Kirkin JK, Naftel DC, Stevenson LW, Kormos
RL, Pagani FD, Miller MA, et al. INTERMACS da-
tabase for durable devices for circulatory support:
first annual report. J Heart Lung Transplant. 2008
Oct;27(10):1055-72.

81. Wilson SR, Mudge GH, Jr., Stewart GC, Givertz
MM. Evaluation for a ventricular assist device:
selecting the appropriate candidate. Circulation.
2009 Apr 28;119(16):2225-32.